Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Procter & Gamble

Procter & Gamble and Johnson & Johnson are Dividend Kings with impressive dividend growth track records. Both companies have strong revenue growth prospects and solid free cash flow coverage of their dividends.

2 Dividend Kings For A Potentially Comfortable Retirement

Chevron

Hess

Realty Income Corp

This integrated giant is a safer way for investors looking to get positioned in the energy sector and pays a rich 4.10% dividend.

5 Dividend Aristocrats That Are Also Wall Street Top Stock Ideas For 2024

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?

Bank of America

JPMorgan Chase & Co

Lowe's

McDonald's

Target

Walmart

Certain stocks stand out as stalwarts in finance and commerce, charting a course toward serious wealth accumulation. The strategies of these seven companies reveal a tapestry of edgy leadership.

7 Must-Have Stocks for Serious Wealth Accumulation

Get a deeper insight into the potential performance of Johnson & Johnson (JNJ) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q4 Earnings

Asensus Surgical

Editas Medicine

Hologic

Illumina

Moderna

Verve Therapeutics

With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from permanent relevance.

7 Mighty Healthcare Stocks Changing the Game of Medicine

Johnson & Johnson (NYSE:JNJ) raised its full-year guidance after a strong third quarter which saw earnings beat expectations and its product pipeline advance. Still, Wall Street expects the New Brunswick, New Jersey-based pharmaceutical giant to post a dip in earnings when it reports back for the fourth quarter next Tuesday.

Johnson & Johnson likely to post dip in 4Q earnings

JNJ stock occupies a top spot in many portfolios due to its consistent performance and low volatility. But should we really and readily accept JNJ as a SWAN stock? A fresh look at Johnson & Johnson is warranted, especially in light of the split-off of its Consumer Health segment (Kenvue stock) and amid the ongoing talc litigation. I share my view on JNJ's two remaining segments, their future prospects, and the decline in cash flow due to the split-off of the Consumer Health segment.

Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off?

General Motors

With Wall Street jubilant about avoiding a recession last year, investors may want to continue betting on the same horse, although here's the thing: targeting undervalued value stocks may offer a more sensible approach. You don't necessarily want to abandon your winners outright.

The 3 Most Undervalued Value Stocks to Buy in January

I recently purchased 15 shares of Johnson & Johnson, and discuss how it fits into my dividend cash machine. I emphasize the importance of dividend cash and compounding in building wealth over time. I rate JNJ as a buy, but only at the current price and with a rational margin of safety. I also suggest considering other dividend-paying stocks for higher starting dividends or more growth potential.

Johnson & Johnson: One Penny, Per Hour, Forever

Berkshire Hathaway sold its entire stakes in Johnson & Johnson and Proctor & Gamble late last year. Johnson & Johnson is an attractively priced dividend stock with a strong growth outlook.

2 Former Warren Buffett Stocks That Stand Out as Stong Buys in 2024

Coca-Cola

Companies that sell everyday products you know well may be the key to your future wealth. They may offer you earnings growth over time and annual dividend payments.

2 Average Stocks That Could Make You Rich

Dow Inc

Innovative Industrial Properties

Pfizer

PennantPark Investment

Walgreens

For inventors looking for a financial compass to navigate the sea of investments, here is the realm of the “Dividend Dynasty.” Here, seven high-yield stocks stand as pillars of long-term wealth accumulation.

Dividend Dynasty: 7 High-Yield Stocks for Long-Term Wealth Accumulation

Lancaster Colony

Investing in companies that have raised their payouts annually for six decades or more has paid off over the long haul.

These Dividend Kings Have Raised Their Payouts for 60 Years or More.

AbbVie

Amcor Plc

Air Products and Chemicals

Franklin Resources

Cincinnati Financial

Federal Realty Investment Trust

Genuine Parts

NextEra Energy

PepsiCo

T. Rowe Price Group

Exxon Mobil

"Dividend Aristocrats. in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years."--Kiplinger.com/Investing.

3 Dividend Aristocrats Signal Buy In January With 7 To Watch

SPDR Dow Jones Industrial Average ETF

Goldman Sachs

Intel

UnitedHealth Group

Let's delve deeper into the probable fourth-quarter earnings picture that will likely aid Dow ETF in the coming days.

Will Q4 Earnings Push Dow ETF Higher?

The latest trading day saw Johnson & Johnson (JNJ) settling at $161.63, representing a +0.06% change from its previous close.

Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Bristol-Myers

iShares Nasdaq Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.

Biotech ETFs Stage Solid Comeback at the Start of 2024

News for Johnson & Johnson Stock (JNJ)